C+ — FMP rating1. Form 4: 6 transactions1.
Quick AnswerMerck & Co., Inc. (MRK) Q4 consensus: revenue $16.4B1, EPS $1.791. 7 consecutive quarters of beat1.
Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
The median of 25 price targets is $1651, stock is $150, +10.4% vs the analyst consensus median.
C+ — FMP rating1. Form 4: 6 transactions1.
Quick AnswerMerck & Co., Inc. (MRK) Q4 consensus: revenue $16.4B1, EPS $1.791. 7 consecutive quarters of beat1.
Next report
Watchlist
Fy2026 Revenue Guidance
Merck raised the midpoint of its FY2026 revenue guidance, narrowing the range to $66.8 billion-$67.3 billion, or 3% to 4% growth.
"We now expect revenue to be between $66.8 billion and $67.3 billion representing growth of 3% to 4% including a positive impact from foreign exchange of approximately 1 percentage point using mid October rates."
- Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026
Winrevair Growth
WINREVAIR global sales rose 94% to $694 million, aided partly by channel inventory.
Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026Keytruda Q3 Growth
The KEYTRUDA family grew 6% to $8.6 billion in Q3.
Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 20262027 Outlook Headwinds
2027_outlook_headwinds
Merck expects moderate top-line growth in 2027, with new launches and animal health partly offsetting more than $2 billion of generic and LOE headwinds.
Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026Sac Tmt Endometrial Data
sac-TMT's Phase III endometrial cancer study showed a near 7-month improvement in median overall survival versus chemotherapy.
Dean Y. Li, President of Merck Research Labs - Q3 FY26 Earnings Call - October 29, 2026Q3 Purchase Timing Benefit
Q3 sales were boosted by about $550 million from U.S. purchase timing, which will unwind largely in Q4 and in 2027.
Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026Stock Expert AI - Methodology
Historical V1 earnings-model score (archived, Nov 1, 2026) — not the current MoonshotScore. Current MoonshotScore: MRK stock page
multi-pillar methodology. Gross Margin and Cash Runway strong. R&D Intensity weak.
How is it calculated? ->6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
No RPO/backlog concentration disclosed in Q3 earnings call.
Form 4 Q3 FY26: 6 transactions, net -$17.93M1.
6 transactions · 6 sales / 0 purchases = net negative flow. Not large in absolute terms against a $368.9B market cap.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Tuesday evening. The framework is ready on this page: Q4 EPS threshold $1.791, CapEx threshold "below $893.0M". Two anchors, three scenarios.
Comparison Stock Expert AI is free today — no credit card.
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This Merck & Co., Inc. (MRK) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Merck & Co., Inc. (MRK): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.
Merck & Co., Inc. (MRK): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.
Merck & Co., Inc. (MRK): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.